Investigational drug · Phase 2
MBK-01
Also called: Fecal Microbiota Transplantation, Intestinal Microbiota Transplantation
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Diverticulitis, Diverticulitis of Sigmoid.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 5, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "MBK-01"
First trial start
2025
Apr 3, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MBK-01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diverticulitis
- Diverticulitis of Sigmoid
Largest trials
Live from ClinicalTrials.gov: studies naming "MBK-01" as an intervention, largest first.
Instituto de Investigación Marqués de ValdecillaAcademic, hospital or other
NCT05622526 · 96 participants (planned) · Start Jan 1, 2024 · Primary completion Nov 1, 2025
Drug: Group 1 or Experimental group · For: Patients With Nonalcoholic Steatohepatitis
- Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs FidaxomicinPivotal-lookingCompleted
Mikrobiomik Healthcare Company S.L.Industry
NCT05201079 · 93 participants · Start Oct 29, 2021 · Primary completion Nov 15, 2023
Drug: MBK-01; Fidaxomicin · For: Recurrent Clostridium Difficile Infection; Primary Clostridium Difficile Infection
Sites: Santander, Spain; Alicante, Spain; Barakaldo, Spain · 21 sites in all
Mikrobiomik Healthcare Company S.L.Industry
NCT06687382 · 81 participants (planned) · Start Apr 3, 2025 · Primary completion Apr 2027
Drug: MBK-01; MBK-01 · For: Diverticulitis; Diverticulitis of Sigmoid
Sites: Madrid, Spain
Newest research
PubMed records naming it or its code names, newest first.
- Siwu Paste alleviates blood deficiency syndrome induced by cyclophosphamide and acetylphenylhydrazine in association with gut microbiota remodeling and improved splenic metabolic homeostasis.
Wan D, Feng X, Xu S, et al. · J Ethnopharmacol 2027
- Tao-He-Cheng-Qi decoction protects against sepsis-associated acute lung injury by modulating gut microbiota and succinate-associated pulmonary macrophage polarization.
Huo W, Hou X, Huang Y, et al. · J Ethnopharmacol 2027
- Yupingfeng alleviates allergic rhinitis by modulating gut microbiota and succinate to inhibit mTOR/S6K signaling.
Zuo Y, Li Y, Huang Z, et al. · J Ethnopharmacol 2027
- Diallyl sulfide pretreatment protects against DSS-induced colitis by reshaping the gut microbiota and enhancing microbiota-associated tryptophan metabolism.
Wan X, Wu Y, Sun Y, et al. · J Ethnopharmacol 2027
- Water-responsive injectable hydrogel achieving rapid in situ gelation and long-term colonic mucoadhesion for efficient fecal microbiota transplantation.
Chen Z, Li Y, Xiong W, et al. · Bioact Mater 2027
- Mechanistic insights into Cistanche deserticola aqueous extract in alleviating functional constipation: Integration of gut microbiota remodeling and focal adhesion-associated mucosal repair.
Hu J, Ma X, Wang Y, et al. · J Ethnopharmacol 2027
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.